共 50 条
- [21] Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose StudyADVANCES IN THERAPY, 2023, 40 (09) : 3804 - 3816Zheng, MinChen, XiangWang, FengChen, JisuJackson, KimberleyYang, FanPayne, ChristopherLi, HongYingWang, YiHuiXiao, ZiPeiZheng, Jie
- [22] Anti-IL21 Receptor Monoclonal Antibody (ATR-107): Safety, Pharmacokinetics, and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First-in-Human StudyJOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (01): : 14 - 22Hua, FeiComer, Gail M.Stockert, LoriJin, BoNowak, JohnPleasic-Williams, SusanWunderlich, DavidCheng, JohnBeebe, Jean S.
- [23] Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque PsoriasisJOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05) : 613 - 627Yao, ZhenlingHu, ChuanpuZhu, YaoweiXu, ZhenhuaRandazzo, BruceWasfi, YasmineChen, YangSharma, AmarnathZhou, Honghui
- [24] Effectiveness and Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis in Real-World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance StudyJOURNAL OF DERMATOLOGY, 2025,Shin, Bong SeokKim, MiriSuh, Moo KyuLee, Young BokYoun, Sang WoongLee, Ji YeounKim, Chul WooLee, Ga-YoungSon, Sang WookKim, Kwang HoAn, JihyeKim, YoungdoeKim, Kwang JoongKim, Dong Hyun
- [25] First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I studyEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159Shen, QiHu, ChaoMiao, JiaChen, JunxiaPeng, YueyingPan, TingtingHe, XiaolinYuan, JingNi, ShaonanWang, YongshengLuo, Zhu
- [26] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42Puig, L.Tsai, T. -F.Bhutani, T.Uy, J.Ramachandran, P.Song, M.You, Y.Gooderham, M.Lebwohl, M.
- [27] First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjectsINVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1826 - 1835Wang, Meng-naKuang, YunGong, Li-yingHua, YePei, QiGuo, Cheng-xianCao, YuHuang, JieYang, Guo-ping
- [28] First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjectsInvestigational New Drugs, 2020, 38 : 1826 - 1835Meng-na WangYun KuangLi-ying GongYe HuaQi PeiCheng-xian GuoYu CaoJie HuangGuo-ping Yang
- [29] First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy AdultsANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (11)Mammen, Mammen P.Armas, DanielleHughes, Frank H.Hopkins, Andrew M.Fisher, Cindy L.Resch, Pamela A.Rusalov, DenisSullivan, Sean M.Smith, Larry R.
- [30] A Semi-Mechanistic Model to Characterize the Pharmacokinetics and Pharmacodynamics of Brodalumab in Healthy Volunteers and Subjects With Psoriasis in a First-in-Human Single Ascending Dose StudyCLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 276 - 283Salinger, David H.Endres, Christopher J.Martin, David A.Gibbs, Megan A.